Genómica traslacional y terapias dirigidas en tumores sólidos
Publicaciones destacadas
-
Immune organization defines adaptive immune competence and clinical outcome in breast cancer
Esther Sanfeliu; Elia Seguí; Anabel Martínez-Romero; Víctor Albarrán; Tomás Pascual;(...)Charles M. Perou; Elı́as Campo; Josep Tabernero; Fara Brasó‐Maristany; Aleix Prat.Referencia:Immuno-Oncology and Technology 2026.
-
Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO)
Pascual, T; Vidal, M; Cejalvo, JM; Vega, E; Sanfeliu, E;(...)O'Connell, CE; Ferrero-Cafiero, JM; Oliveira, M; Perou, CM; Prat, A.Referencia:Nature Communications 2026.
-
HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis
Villacampa, Guillermo; Pascual, Tomas; Tarantino, Paolo; Cortes, Javier; Perez-Garcia, Jose;(...)Perou, Charles M; Pare, Laia; Villagrasa, Patricia; Prat, Aleix; Tolaney, Sara M.Referencia:LANCET ONCOLOGY 2025.
-
TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy
Martin, M; Stecklein, S R; Gluz, O; Villacampa, G; Monte-Millan, M;(...)Perou, C M; Villagrasa, P; Prat, A; Sharma, P; Harbeck, N.Referencia:ANNALS OF ONCOLOGY 2025.
-
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response
Braso-Maristany, Fara; Ferrero-Cafiero, Juan Manuel; Falato, Claudette; Martinez-Saez, Olga; Cejalvo, Juan Miguel;(...)Suto, Fumitaka; Vivancos, Ana; Pascual, Tomas; Prat, Aleix; Oliveira, Mafalda.Referencia:Nature Communications 2024.
-
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer
Prat, Aleix; Braso-Maristany, Fara; Martinez-Saez, Olga; Sanfeliu, Esther; Xia, Youli;(...)Gonzalez-Farre, Blanca; Villagrasa, Patricia; Parker, Joel S; Perou, Charles M; Vivancos, Ana.Referencia:Nature Communications 2023.
-
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
Prat, Aleix; Guarneri, Valentina; Pascual, Tomas; Braso-Maristany, Fara; Sanfeliu, Esther;(...)Vivancos, Ana; Villagrasa, Patricia; Parker, Joel S; Conte, Pierfranco; Perou, Charles M.Referencia:EBioMedicine 2022.
-
Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies
Prat, Aleix; Chaudhury, Anwesha; Solovieff, Nadia; Pare, Laia; Martinez, Debora;(...)Braso-Maristany, Fara; Lteif, Agnes; Taran, Tetiana; Babbar, Naveen; Su, Fei.Referencia:JOURNAL OF CLINICAL ONCOLOGY 2021.
-
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial
Prat, Aleix; Saura, Cristina; Pascual, Tomas; Hernando, Cristina; Munoz, Montserrat;(...)Lopez, Rafael; Celiz, Pamela; Ciruelos, Eva; Villagrasa, Patricia; Gavila, Joaquin.Referencia:LANCET ONCOLOGY 2020.
